FOCUS-C9 (NCT04931862) was a phase 1b/2a randomized double-blind placebo controlled trial using intrathecal administration of WVE-004, an ASO targeting C9orf72 repeat-containing mRNA, in FTD and ALS. Here, C9orf72 is linked to amyotrophic lateral sclerosis.